Difference between revisions of "Zanubrutinib (Brukinsa)"
Jump to navigation
Jump to search
(Created page with "==General information== Class/mechanism: BTK inhibitor <br>Route: PO <br>Extravasation: n/a For conciseness and simplicity, HemOnc.org currently will focus on treatment regim...") |
|||
| Line 12: | Line 12: | ||
==History of changes in FDA indication== | ==History of changes in FDA indication== | ||
| − | *11/14/2019: | + | *11/14/2019: Granted accelerated approval for adult patients with [[mantle cell lymphoma|mantle cell lymphoma (MCL)]] who have received at least one prior therapy. |
==Also known as== | ==Also known as== | ||
Revision as of 04:13, 16 November 2019
General information
Class/mechanism: BTK inhibitor
Route: PO
Extravasation: n/a
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, UpToDate (courtesy of Lexicomp), or the prescribing information.
Diseases for which it is used
Patient drug information
History of changes in FDA indication
- 11/14/2019: Granted accelerated approval for adult patients with mantle cell lymphoma (MCL) who have received at least one prior therapy.
Also known as
- Code name: BGB-3111
- Brand name: Brukinsa